English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Blockade of programmed death-1 (PD-1) reinvigorates exhausted CD8 + T cells, resulting in tumor regression in cancer patients. Recently, reinvigoration of exhausted CD8 + T cells following PD-1 blockade was shown to be CD28-dependent in mouse models. Herein, we examined the role of CD28 in anti-PD-1 antibody-induced human T cell reinvigoration using tumor-infiltrating CD8 + T cells (CD8 + TILs) obtained from non-small-cell lung cancer patients. Single-cell analysis demonstrated a distinct expression pattern of CD28 between mouse and human CD8 + TILs. Furthermore, we found that human CD28 + CD8 + but not CD28 - CD8 + TILs responded to PD-1 blockade irrespective of B7/CD28 blockade, indicating that CD28 costimulation in human CD8 + TILs is dispensable for PD-1 blockade-induced reinvigoration and that loss of CD28 expression serves as a marker of anti-PD-1 antibody-unresponsive CD8 + TILs. Transcriptionally and phenotypically, PD-1 blockade-unresponsive human CD28 - PD-1 + CD8 + TILs exhibited characteristics of terminally exhausted CD8 + T cells with low TCF1 expression. Notably, CD28 - PD-1 + CD8 + TILs had preserved machinery to respond to IL-15, and IL-15 treatment enhanced the proliferation of CD28 - PD-1 + CD8 + TILs as well as CD28 + PD-1 + CD8 + TILs. Taken together, these results show that loss of CD28 expression is a marker of PD-1 blockade-unresponsive human CD8 + TILs with a TCF1 - signature and provide mechanistic insights into combining IL-15 with anti-PD-1 antibodies.

PD-1 blockade-unresponsive human tumor-infiltrating CD8+ T cells are marked by loss of CD28 expression and rescued by IL-15